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P. Vasudeva Chetty aa Department of Cardiology, SVIMS, Tirupati, Andhra Pradesh
a IndiaAim: To examine the relationship between plasma levels of N-terminal-proB type natriuretic peptide (NT-proBNP)
and various echocardiographic and hemodynamic parameters in patients with mitral stenosis undergoing percutaneous
transvenous mitral commissurotomy (PTMC).
Materials and methods: The study population consisted of 100 patients with rheumatic mitral stenosis who under-
went PTMC. NT-proBNP levels in these patients were measured before PTMC and 48 hours after PTMC. These levels
were then correlatedwith various echocardiographic and hemodynamic parametersmeasured before and after PTMC.
Results: Eighty-one percent of the study population were women, and the most common presenting symptom was
dyspnea whichwas present in 94% of the patients. Dyspnea NewYorkHeart Association class correlated significantly
with baseline NT-proBNP levels (r = 0.63; p < 0.01). The plasma NT-proBNP levels in these patients increased as
echocardiogram signs of left atrial enlargement and right ventricular hypertrophy developed (r = 0.59, p < 0.01).
Patients in atrial fibrillation had significantly higher NT-proBNP levels than patients in sinus rhythm. Baseline
NT-proBNP levels correlated significantly with left atrial volume (r = 0.38; p < 0.01), left atrial volume index (r = 0.45;
p < 0.01), systolic pulmonary artery pressures (r = 0.42; p < 0.01), and mean pulmonary artery pressures (r = 0.41;
p < 0.01). All patients who underwent successful PTMC showed a significant decrease in NT-proBNP (decreased from
amean 763.8 pg/mL to 348.6 pg/mL) along with a significant improvement in all echocardiographic and hemodynamic
parameters (p < 0.01). The percent change in NT-proBNP correlated significantly with the percent improvement noted
with left atrial volume (r = 0.39;p < 0.01), left atrial volume index (r = 0.41;p < 0.01), systolic (r = 0.32,p < 0.01), andmean
pulmonary artery pressures (r = 0.31, p < 0.01).
Conclusions: The decrease in NT-proBNP levels following PTMC reflects an improvement in clinical and
hemodynamic status; hence, it is reasonable to suggest thatNT-proBNP is helpful in evaluating the response to PTMC.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).e CC BY-
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NT-proBNP N-terminal-pro B type natriuretic peptide
PTMC Percutaneous transvenous mitral commissurotomy
RHD Rheumatic heart disease
RF Rheumatic fever
MS Mitral stenosis
MVA Mitral valve area
LA left atrium
PA Pulmonary artery
BNP Brain natriuretic peptide
NPs natriuretic peptides
LAVI Left atrial volume index
LVEDP left atrial end diastolic pressure
AF Atrial fibrillation
NYHA New York Heart AssociationIntroduction
Rheumatic heart disease (RHD) is a permanentsequelae of rheumatic fever (RF). The preva-
lence of RF and RHD has decreased in developed
countries, but they still remain a major health haz-
ard in developing countries. The incidence of RF is
equal in both genders, but rheumatic mitral steno-
sis (MS) is two times more common in women [1].
Rheumatic fever affects all the valves micro-
scopically, but clinically significant disease is
observed mostly in the mitral valve [1]. Mitral
stenosis being a mechanical obstruction to the for-
ward flow of blood, the only definitive therapy is a
mechanical relief in this obstruction. Three proce-
dures are effective in providing such therapy,
which are percutaneous transvenous mitral com-
missurotomy (PTMC), surgical mitral commis-
surotomy, and mitral valve replacement. A
successful PTMC results in improvement in mitral
valve area (MVA), thereby causing a decrease in
left atrial (LA) pressures, decrease in pulmonary
artery (PA) pressures, and increase in left ventric-
ular end diastolic pressure.
Brain natriuretic peptide (BNP), a cardiac neuro-
hormone secreted predominantly by ventricles
and to some extent by atria, has a regulatory and
modulatory role in the cardiovascular system by
its diuretic, natriuretic, and vasodilator actions.
N-terminal-pro B type natriuretic peptide
(NT-proBNP) is part of prepro-BNP, which is
secreted in a proportion equivalent to BNP. It is
more stable than BNP due to its long half-life,
therefore higher levels of NT-proBNP are
observed. The diagnostic and prognostic role of
NT-proBNP in left ventricular dysfunction of
various etiologies has been extensively studied
[2–4]. It has also been shown in studies that
plasma NT-proBNP levels increase in diseases like
primary pulmonary hypertension, cor-pulmonale,
and pulmonary embolism which affect the
pulmonary bed and right heart [5,6].
The prognostic role of various NPs in valvular
heart diseases has been extensively studied
[7–9]. It was noted that various NPs were elevated
in patients of MS, and few of them correlated with
the severity of MS [7]. Following a successful
PTMC, a decrease in various NPs is expected
and few studies have evaluated this change
[10,11]. Although NT-pro-atrial-NPs are increasedin patients of MS along with BNP and
NT-proBNP, due to the ease of laboratory tests
and reproducibility usually only BNP or
NT-proBNP is used. Plasma NT-proBNP levels
are affected in MS and they correlate with the
severity of MS [12–17]. Only a few studies have
evaluated the change in NT-proBNP levels in
patients of severe MS following PTMC [18–23].
The reversible nature of the pulmonary hyper-
tension in MS may be an explanation for the
decrease in NT-proBNP levels after PTMC. The
decrease in pressures in the LA and right side of
the heart following PTMC cause a decrease in
wall stress which contributes to the decreased
NT-proBNP levels. This present study is designed
to examine the relationship between plasma levels
of NT-proBNP and various echocardiographic and
hemodynamic parameters in patients with MS
undergoing PTMC.Materials and methods
The study population consisted of 100 patients
with rheumatic severe MS who underwent PTMC
at department of Cardiology, Sri Venkateswara
Institute of Medical Sciences, Tirupati, India
between June 2012 and November 2013. The pro-
tocol was approved by the Institutional Ethics
Committee and all patients gave a written
informed consent. All patients with severe MS
[2-dimensional (2D) MVA = 1.5 cm2] who were
candidates for PTMC, as per ACC/AHA/ESC
guidelines, were included in this study [24,25].
Inclusion criteria were patients with symptomatic
severe MS with favorable valve morphology,
Table 1. Demographic data; dyspnea New York Heart
Association class and N-terminal-pro B type natriuretic
peptide.
Demographic data (population size n = 100)
Men/women = 19/81
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NT-PROBNP FOLLOWING PTMCasymptomatic patients with severe MS who had
more than moderate PA hypertension
(>50 mmHg), and those at high risk for throm-
boembolic events. All patients with systolic or
diastolic left ventricular dysfunction, systemic
hypertension, cardiomyopathy, chronic diseases
of the respiratory tract, those with concurrent
more than mild mitral regurgitation (MR), aortic
stenosis and/or regurgitation, left ventricular
hypertrophy confirmed with echocardiography,
renal failure, hepatic failure, and those developing
severe MR following PTMC requiring immediate
surgical intervention were excluded from the
study.
Transthoracic, M-mode, 2D, and Doppler
echocardiography were performed and LA
volume, left atrial volume index (LAVI), mitral
valve gradient, 2D-MVA, and PA pressures
were measured on the day before and 48 hours
after PTMC using Philips IE-33 machine, Holland.
All patients underwent transesophageal
echocardiography 24 hours before PTMC in order
to exclude the presence of LA thrombus and to
assess valve morphology.
Hemodynamic measurements (LA pressure,
LVEDP, systolic and mean PA pressures, mean
and end diastolic pressure gradient across the
mitral valve) were recorded before and immedi-
ately after PTMC.
Mitral valve commissurotomy was performed
with an Accura balloon catheter (Vascular con-
cepts, Essex, UK) using the Inoue technique [26].
A 2-mL blood sample was collected with
venipuncture into heparinised tubes 30 minutes
before PTMC and 48 hours after PTMC.
NT-proBNP levels were measured using Roche
CARDIAC proBNP test kit (code 04659449190,
Roche Diagnostics Ltd., Germany) and Cobas h
232 Point Of Care system. The reaction time
for the assay is about 10–15 minutes and the
detection range of the assay is 60–9000 pg/mL of
NT-proBNP.Variable Range Mean ± SD
Age (y) 13–63 37.5 ± 11
Height (cm) 128–176 150.4 ± 9
Weight (kg) 22–75 47.1 ± 10.7
Body surface area (m2) 0.88–1.86 1.43 ± 0.18
Dyspnea
NHYA
class
No. of
patients
NT-proBNP
pg/ml
(mean ± SD)
NT-proBNP
pg/mL
(range)
Class I 2 97 87–107
Class II 57 461.2 ± 355.6 80–2207
Class III 40 1186.3 ± 666.5 210–6635
Class IV 1 8013
r = 0.63 ; p < 0.01
NT-proBNP = N-terminal brain natriuretic peptide; NYHA = New York
Heart Association; SD = standard deviation.Statistical analysis
Data collected was tabulated on a Microsoft Excel
spread sheet and analyzed with IBM SPSS Statis-
tics for Windows, Version 20.0. Armonk, NY: IBM
Corp. Paired t test was used for intragroup compar-
isons. Correlation coefficient was used to assess the
linear relation between two variables. As the
plasma NT-proBNP levels were widely distributed,
logarithmic (log) transformed values were used for
correlation tests. The relation between NT-proBNP
levels and dyspnea New York Heart Association
(NYHA) class were assessed using Spearman’scorrelation test. The relationship between NT-
proBNP levels and electrocardiogram (ECG)
changes were assessed using Spearman’s correla-
tion test. The relation between log NT-proBNP
levels and echocardiographic and hemodynamic
parameters were assessed using the Pearson corre-
lation test. The percentage decrease in NT-proBNP
levels and percentage change in various variables
were assessed using the Pearson correlation test.
A value of p < 0.05 was considered significant.Results
Baseline characteristics of the study population
Most of the study population were women. The
men to women ratio was 19:81. The mean age of
the study population was 37.5 ± 11 years ranging
between 13 and 63 years with the majority being
below 40 years (62%) of age. The patients height
ranged from 128 to 176 cm, with the mean height
being 150.4 ± 9 cm. The body surface area of the
patients ranged between 0.88 and 1.86 m2 and
the mean body surface area was 1.43 ± 0.18 m2.
Most of the patients were diagnosed with severe
MS during their first evaluation. The most com-
mon presenting complaint was dyspnea, which
was present in 94% of the patients. Two percent
of patients presented with predominant palpita-
tions which were due to atrial fibrillation (AF) with
a fast ventricular rate and 2% presented with
hemoptysis.
History suggestive of RF in the past was present
in only 21% of the patients, among whom one
patient had a history of chorea. Thirteen percent
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and a repeat PTMC was performed in view of sev-
ere mitral restenosis. History of a cerebrovascular
accident was present in 3% of the patients. All
three patients were diagnosed with severe MS
during their evaluation for cerebrovascular acci-
dent (Table 1).
Dyspnea NYHA class and NT-proBNP level
It was observed that as the dyspnea NYHA class
worsened, the mean NT-proBNP levels increased
and there was a significant correlation between
dyspnea NYHA class and NT-proBNP levels
(r = 0.63, p < 0.01). The mean NT-proBNP level in
clinically stable patients (NYHA class I, II) was
443.9 pg/mL and the mean NT-proBNP level in
patients with pulmonary edema (NYHA class III,
IV) was 1380 pg/mL (Table 1).
ECG findings and NT-proBNP level
In patients of MS who were in sinus rhythm
(SR), those with evidence of right ventricular
(RV) hypertrophy, along with LA enlargementTable 2. Electrocardiogram and N-terminal brain natriuretic peptid
ECG No. of patients
SR, LAE 50
SR, LAE, Rt axis 18
SR, LAE, Rt axis, RBBB/RVH ± strain 19
AF with CVR/FVR 13
r = 0.59; p < 0.01
AF = atrial fibrillation; CVR = controlled ventricular rate; ECG = electrocardio
BNP = N-terminal brain natriuretic peptide; RBBB = right bundle branch
deviation; SR = sinus rhythm.
Table 3. Correlation of various parameters with N-terminal brai
commissurotomy.
Parameter Pre-PTMC
Echocardiographic parameters
2D MVA (cm2) 0.98 ± 0.15
LA diameter (cm) 4.2 ± 0.5
LA volume (cm3) 69.1 ± 19.2
LA volume index (cm3/m2) 48.6 ± 14.4
Hemodynamic parameters
a wave (mmHg) 26.3 ± 7.3
v wave (mmHg) 28.5 ± 9.6
Mean AP (mmHg) 21.4 ± 6.8
LV EDP (mmHg) 6.5 ± 2.6
Systolic PA pressure (mmHg) 53.7±21.7
Mean PA pressure(mmHg) 35 ± 15
a-EDP gr (mmHg) 19.7 ± 7
m-EDP gr (mmHg) 15.3 ± 6.9
NT pro BNP (pg/mL) 763.8 ± 640.7
a-EDP = left atrial a wave-left ventricular end diastolic pressure; AP = atr
pressure; MVA = mitral valve area; m-EDP = mean left atrial pressure-lef
natriuretic peptide; PA = pulmonary artery; PTMC = percutaneous transvenon ECG had higher levels of NT-proBNP than
those with only LA enlargement. Patients in AF,
despite their ventricular rate (fast/controlled),
had higher BNP levels compared with those in
SR. Mean NT-proBNP levels in patients with AF
was 2358.6 pg/mL. A significant correlation was
noted between these ECG changes and
NT-proBNP levels (r = 0.59, p < 0.01) (Table 2).
Correlation of NT-proBNP levels with various
echocardiographic and hemodynamic parameters
at baseline (pre-PTMC)
Owing to the wide dispersion of data for
NT-proBNP, log NT-proBNP was calculated. The
relationship between log NT-proBNP levels and
various echocardiographic and hemodynamic
parameters were assessed using the Pearson
correlation test. On correlation with various
echocardiographic parameters, it was observed
that log NT-proBNP correlated significantly
with LA volume (r = 0.38; p < 0.01) and LAVI
(r = 0.45; p < 0.01). On correlation with various
hemodynamic parameters, it was observed thate levels.
NT-proBNP pg/mL
(mean ± SD)
NT-proBNP pg/mL
(range)
477.7 ± 362 100–1516
659.3 ± 501.7 80–1796
1275.5 ± 784.9 253–8013
2358.6 ± 1764.4 1030–6635
gram; FVR = fast ventricular rate; LAE = left atrial enlargement; NT-pro
block; Rt = right; RVH = right ventricular hypertrophy; SD = standard
n natriuretic peptide before percutaneous transvenous mitral
Correlation coefficient (r value) p
0.19 0.07
0.21 0.04
0.38 <0.01
0.45 <0.01
0.18 0.1
0.28 <0.01
0.22 0.03
0.03 0.75
0.42 <0.01
0.41 <0.01
0.01 0.94
0.21 0.04
ial pressures; LA = left atrium; LVEDP = left ventricular end diastolic
t ventricular end diastolic pressure; NT-pro BNP = N-terminal brain
ous mitral commissurotomy.
Table 4. Changes in echocardiographic and hemodynamic parameters and N-terminal brain natriuretic peptide following
percutaneous transvenous mitral commissurotomy.
Variables Pre Post Diff p
Echocardiographic parameters
2D MVA (cm2) Mean range 0.98 ± 0.15
0.5–1
1.90 ± 0.30
1.1–2
0.95 ± 0.23
0.4–1.4
<0.01
LA diameter (cm) Mean range 4.2 ± 0.5
2.9–5.8
3.8 ± 0.5
2.4–5
0.4 ± 0.3
0.2–1
<0.01
LA volume (cm3) Mean range 69.1 ± 19.2
35.5–132.5
55.1 ± 18
23.7–120.8
13.9 ± 7.6
3.4–34.7
<0.01
LA volume index (cm3/m2) Mean range 48.6 ± 14.4
27.2–92.7
38.8 ± 12.9
16.8–78.4
9.8 ± 5.4
0.4–26.8
<0.01
Hemodynamic parameters
a wave (mmHg) Mean range 26.3 ± 7.3
12–43
15.6 ± 6.4
6–38
10.8 ± 5.4
1–28
<0.01
v wave (mmHg) Mean range 28.5 ± 9.6
10–56
16.2 ± 6.9
4–40
12.2 ± 6.1
3–34
<0.01
Mean AP (mmHg) Mean range 21.4 ± 6.8
12–79
11.4 ± 4.8
6 – 60
10 ± 4.3
2–29
<0.01
LV EDP (mmHg) Mean range 6.5 ± 2.6
2–16
9.3 ± 2.6
4–17
2.8 ± 1.3
1–6
<0.01
PA peak (mmHg) Mean range 53.7 ± 21.7
23–134
39.1 ± 16
12–97
14.6 ± 11.7
2–53
<0.01
D2 peak PA (mmHg) Mean range 53.7 ± 21.7
23–134
31.6 ± 13
12–70
22.1 ± 15.9
4–63
<0.01
PA mean (mmHg) Mean range 35 ± 15
12–79
24.5 ± 10.5
6–60
10.5 ± 8.6
2–29
<0.01
a-EDP gr (mmHg) Mean range 19.7 ± 7
4–37
6.4 ± 5.3
2–26
13.4 ± 5.8
3–28
<0.01
m-EDP gr (mmHg) Mean range 15.3 ± 6.9
5–43
2.4 ± 2.3
0–16
12.7 ± 5
5–27
<0.01
NT-proBNP (pg/ml) Mean range 763.8 ± 640.7
80–8013
348.6 ± 301.5
60–5599
377.6 ± 359.2
10–5790
<0.01
a-EDP = mitral end diastolic gradient (LA a wave – LV EDP); AP = atrial pressure; D2 peak PA = pulmonary artery systolic pressures after 48 hours;
LA = left atrium; LVEDP = left ventricular end diastolic pressure; m-EDP = mean mitral pressure gradient (LA mean pressure–LV EDP); MVA: mitral
valve area; NT-proBNP: N-terminal brain natriuretic peptide; PA = pulmonary artery pressure.
Table 5. Difference in N-terminal brain natriuretic peptide following percutaneous transvenous mitral commissurotomy in patients
with atrial fibrillation (n = 12) and sinus rhythm (n = 80).
Rhythm NT-proBNP prePTMC pg/mL
mean ± SD
NT pro BNP postPTMC pg/ml
mean ± SD
Paired Student t test
AF (n = 12) 2468.1 ± 860.2 1131.2 ± 530.6 0.018
SR (n = 80) 701.6 ± 582.4 284.6 ± 244.6 <0.01
AF = atrial fibrillation; NT-pro BNP = N-terminal brain natriuretic peptide; SD = standard deviation; S = sinus rhythm.
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NT-PROBNP FOLLOWING PTMClog NT-proBNP showed significant correlation
with systolic PA pressures (r = 0.42; p < 0.01) and
the mean PA pressures (r = 0.41; p < 0.01) (Table 3).Changes in echocardiographic parameters,
hemodynamic parameters, and NT-proBNP levels
following PTMC
Ninety-two patients underwent successful
PTMC. Four patients developed moderate to sev-
ere MR and four others developed AF (lasting
>24 hours) following PTMC (Table 4). In patients
who underwent successful PTMC (n = 92), all
echocardiographic and hemodynamic parametersshowed a significant improvement (p < 0.01).
NT-proBNP levels decreased significantly
following PTMC (p < 0.01). A significant decrease
in NT-proBNP levels was observed both in
patients with AF (p < 0.05) and also in those with
SR (p < 0.01) (Table 5).Correlation between change in various
echocardiographic and hemodynamic parameters
with change in NT-proBNP levels
The percent decrease in NT-proBNP levels cor-
related with percent decrease in LA volume
(r = 0.39; p < 0.01), LAVI (r = 0.41; p < 0.01) on
Table 6. Correlation between percent improvement in various
echocardiographic and hemodynamic parameters with percent
decrease in brain natriuretic peptide.
Parameter Correlation
coefficient
(r value)
p
Echocardiographic parameters
2D MVA (cm2) 0.08 0.43
LA diameter (cm) 0.12 0.25
LA volume (cm3) 0.39 <0.01
LA volume index (cm3/m2) 0.41 <0.01
PA (D2 PAP) mmHg 0.33 <0.01
Hemodynamic parameters
a wave (mmHg) 0.23 0.04
v wave (mmHg) 0.19 0.07
Mean AP (mmHg) 0.17 0.10
LV EDP (mmHg) 0.11 0.29
PA peak (mmHg) 0.32 <0.01
PA mean (mmHg) 0.31 <0.01
a-EDP gr (mmHg) 0.21 0.07
m-EDP gr (mmHg) 0.14 0.17
a-EDP = mitral end diastolic gradient (LA a wave – LV EDP); AP = atrial
pressure; D2 PAP = pulmonary artery systolic pressures after 48 hours;
EDP = mean mitral pressure gradient (LA mean pressure – LV EDP
LA = left atrium; MVA: mitral valve area; NT-pro BNP = N-terminal
brain natriuretic peptide; PA = pulmonary artery pressure.
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significantly with the percent decrease in systolic
PA pressures (r = 0.32; p < 0.01) and mean PA
pressures (r = 0.31; p < 0.01) observed immediately
following PTMC and the decrease in systolic PA
pressures after 48 hours (r = 0.33; p < 0.01). On
multivariate analysis, the percent change in sys-
tolic PA pressures over 48 hours independently
predicted the percent change in NT-proBNP
levels (Table 6).Complications
Four patients developed moderate to severe MR
following PTMC which was commissural. These
patients were managed medically and were
followed-up. A significant increase in
NT-proBNP levels were noted in these patients
following PTMC (p < 0.01). Four other patients
developed AF during or after PTMC lasting for
more than 24 hours. An increase in NT-proBNP
level was noted in these patients despiteTable 7. Change in N-terminal brain natriuretic peptide following
Complication NT pro BNP prePTMC (pg/mL)
Mod–Sev MR (n = 4) 980
AF (>24 h) (n = 4) 309.8
AF = atrial fibrillation; Mod = moderate; MR = mitral regurgitation; NT-pr
transvenous mitral commissurotomy; Sev = severe; SR = sinus rhythm.improvement in all other echocardiographic and
hemodynamic parameters. This increase was not
statistically significant (p = 0.06) (Table 7).Discussion
This present study is the largest to date (n = 100),
evaluating the changes in NT-proBNP levels with
changes in various echocardiographic and hemo-
dynamic parameters following PTMC. History
suggestive of RF in the past was present in only
21% of the study population, which is much less
compared with most of the studies where the
reported incidence of history of RF in patients of
MS was around 50% [1].This shows us the burden
of RF with subclinical carditis in the Indian
population.
Similar to other studies, we noticed an elevated
NT-proBNP level in patients of MS [13–23]. The
most common presenting symptom was dyspnea;
it was present in 94% of the patients. Similar to
Arat Ozkan et al. [14] and Seluck et al. [19], we
observed that NT-proBNP levels correlated signif-
icantly with dyspnea NYHA class of the patients
(Table 1). Clinical symptoms, especially dyspnea,
usually depends on the pulmonary capillary
wedge pressure and PA pressures. This explains
an increase in NT-proBNP level with worsening
NYHA class. Thus, NT-proBNP can be used as a
tool for risk stratification and for monitoring
disease progression in patients of MS.
In patients with MS, significantly higher levels
of NT-proBNP were noted with development of
right axis deviation, RV hypertrophy, and AF on
ECG (Table 2). These ECG changes reflect the
sequential pathophysiological changes noted dur-
ing MS with increasing severity and chronicity. LA
pressures increase with the severity of MS, which
results in increased pulmonary capillary wedge
pressure that in turn leads to increased PA pres-
sures, and thus RV pressure overload, thereby
explaining the increase in NT-proBNP levels.
Atrial fibrillation, however, represents the
chronicity of the disease and thereby a dilated
atria, increased PA pressures, and RV strain.
Atrial fibrillation by itself causes an increased
LA wall stress, thereby causing a further increase
in NT-proBNP levels. This finding was contrary tothe development of complications.
NT pro BNP postPTMC (pg/mL) p
1977.3 0.006
996 0.06
o BNP = N-terminal brain natriuretic peptide; PTMC = percutaneous
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NT-PROBNP FOLLOWING PTMCthat observed by Shang et al. [18] and Chadha
et al. [20], who did not observe any difference in
BNP/NT-proBNP levels between patients in SR
and AF, but these studies were underpowered in
terms of study group size.
Similar to Shang et al. [18], Seluck et al. [19],
Chadha et al. [20], and Esteves et al. [23], a signif-
icant correlation between baseline NT-proBNP
levels and PA pressures (systolic and mean) was
noted. In addition, a significant correlation
between NT-proBNP levels and LA volume (LA
volume and LAVI) on transthoracic echocardio-
gram was also noted (Table 3). The significant pos-
itive correlation between baseline NT-proBNP
levels and PA pressure may reflect the response
of myocytes to chronic elevations of pressures in
RV in MS patients. Studies in patients with lone
AF [27,28] demonstrated a significant correlation
between BNP levels and LAVI, reflecting the pro-
duction of BNP in a stretched LA. This explains
the correlation noted between NT-proBNP levels
and LA volume and LAVI. Similar observations
were reported by Davutoglu et al. [15], who noticed
that in patients with RHD, a higher LA diameter
correlated with a higher NT-proBNP level.
A significant decrease in NT-proBNP levels was
noted following successful PTMC (Table 4); this
was similar to previous studies [18–23]. Unlike
Shang et al. [18] and Chadha et al. [20], a signifi-
cant decrease in NT-proBNP levels were noted
after PTMC, even in patients with AF (Table 5).
A successful PTMC results in a decrease of pres-
sure in LA, pulmonary artery, RV, and also a
decrease in LA volume, which explains an
expected decrease in NT-proBNP levels following
PTMC even in patients with AF.
Similar to Seluck et al. [19], a significant correla-
tion between percent change in NT-proBNP levels
after PTMC and percent change in systolic PA
pressures (immediate and after 48 hours) were
noted (Table 6). A significant correlation has also
been noted with percent decrease in LA volume
and LAVI. The reversible nature of pulmonary
hypertension in patients with MS and the
decrease in LA volume following PTMC are a
reasonable explanation for observed decrease in
NT-proBNP levels.
Change in NT-proBNP level with a change in LA
volume was observed by Therkelsen et al. [27] and
Sacher et al. [28] in patients of lone AF where
following cardio version/ablation they noticed a
decrease in LA volume and decrease in
NT-proBNP level. This observation goes with our
findings, that a significant positive correlation
between NT-proBNP and LA volume exists anda decrease in NT-proBNP level following PTMC
correlates with decrease in LA volume.
Four patients developed moderate-severe MR
following PTMC – a significant increase in NT-
proBNP was noted in them (Table 7). A significant
MR following PTMC results in persistently high
LA and PA pressures in these patients. An addi-
tional volume overload develops in LA and left
ventricle, which might result in augmented secre-
tion of NT-proBNP, thereby resulting in a higher
NT-proBNP level.
Four other patients developed AF (lasting
>24 hours) following PTMC (Table 7). In these
patients, despite improvement in all echocardio-
graphic and hemodynamic parameters, an
increase in NT-proBNP levels was noted. New
onset AF causes an increased tension in LA wall
thereby increasing NT-proBNP which is coun-
tered by a decrease in NT-proBNP following a
successful PTMC, and hence the probable net
result of an insignificant increase in NT-proBNP
levels in this subset of patients.
There are a few limitations in our study. Only
patients with severe MS were studied, hence
changes in NT-proBNP levels with increasing
severity of MS could not be determined. Serial
measurements of NT-proBNP immediately fol-
lowing PTMC, at 24 hours after PTMC, and during
follow-up after 1 month could have added further
information to our findings. Repeat hemodynamic
measurements after 48 hours of PTMC could not
be done as it is an invasive procedure and hence
echocardiographic measurements of PA pressures
and gradients across mitral valve were taken into
consideration.
In conclusion, plasma NT-proBNP levels were
significantly elevated in patients with severe MS,
and they correlated with NYHA functional class
of these patients. The baseline NT-proBNP levels
correlated with LA volume, LAVI, systolic PA
pressures, and mean PA pressures. Along with
all echocardiographic and hemodynamic
parameters, NT-proBNP also showed a significant
improvement following a successful PTMC. The
decrease observed in NT-proBNP levels which is
statistically significant is noted in patients with
SR, and also in those with AF. The decrease in
NT-proBNP levels following PTMC correlated
with decrease in LA volume, LAVI, an immediate
decrease in systolic and mean PA pressures, and
also decrease in PA pressures over 2 days.
The decrease in NT-proBNP levels following
PTMC reflects an improvement in clinical status
and an improvement in various echocardio-
graphic and hemodynamic parameters following
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2016;28:81–88PTMC. Thus, it seems reasonable to suggest that
NT-proBNP is helpful in evaluating the response
to PTMC in patients of severe rheumatic MS.
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